K. Krauss

发表

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

S. Shak, F. Baehner, N. Harbeck, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.

T. Fehm, L. Kanz, F. Mayer, 2011, Anticancer research.

[MR imaging of the breast before and after neoadjuvant treatment - enhancement characteristics and T 2 signal intensity of breast cancers and breast parenchyma].

C. Claussen, U. Vogel, K. Siegmann, 2010, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

N. Harbeck, O. Gluz, S. Kuemmel, 2017 .

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.

N. Harbeck, O. Gluz, S. Kuemmel, 2022, The Lancet. Oncology.

Authors' Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest.

Diethelm Wallwiener, D. Wallwiener, B. Aydeniz, 2004 .

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

N. Harbeck, O. Gluz, S. Kuemmel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole.

D. Wallwiener, J. Huober, K. Sotlar, 2007, Anticancer research.

99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types

F. Mottaghy, E. Stickeler, H. Biersack, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

S. Shak, F. Baehner, N. Harbeck, 2020, Therapeutic advances in medical oncology.

Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section.

D. Wallwiener, B. Aydeniz, J. Huober, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).

N. Harbeck, O. Gluz, S. Kuemmel, 2019 .

Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.

A. Schneeweiss, D. Wallwiener, G. Bastert, 2004, European journal of cancer.

Endocrine Therapy in Early Breast Cancer

E. Stickeler, K. Krauss, 2020, Breast Care.

Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial

M. Hauptmann, S. Shak, N. Harbeck, 2021 .

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

F. Feuerhake, N. Harbeck, O. Gluz, 2022, Clinical Cancer Research.

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

N. Harbeck, O. Gluz, S. Kuemmel, 2021 .